oral glp-1 drugs Lesson: Semaglutide: A New Receptor Agonist Product for the Treatment of Type 2 Diabetes Comparing Ozempic, Wegovy and Other

Description

GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d

Retatrutide vs Semaglutide: Evidence-based comparison of the investigational triple GIP/GLP-1/glucagon agonist versus the FDA-approved GLP-1 agonist

Methods This is a cohort study combining several population-wide databases and covering a Spanish population of five million inhabitants, including all adults with obesity who initiated treatment with either GLP-1RA or SGLT-2i for type 2 diabetes from 2015 to 2021

To further note, in the field of weight-loss treatment, significant work is underway in parallel, on GIP agonist, amylin agonist, glucagon agonist, PYY agonist, either separately or in combination especially with GLP-1 agonist.

The science, promise and clinical development of GLP-1 and GIP receptor agonists in obesity